BR0309357A - Método para fabricar cristais de esteróides, cristais obtìveis de acordo com esse método, e formulações farmacêuticas - Google Patents

Método para fabricar cristais de esteróides, cristais obtìveis de acordo com esse método, e formulações farmacêuticas

Info

Publication number
BR0309357A
BR0309357A BR0309357-3A BR0309357A BR0309357A BR 0309357 A BR0309357 A BR 0309357A BR 0309357 A BR0309357 A BR 0309357A BR 0309357 A BR0309357 A BR 0309357A
Authority
BR
Brazil
Prior art keywords
crystals
pharmaceutical formulations
obtainable
steroid
particle size
Prior art date
Application number
BR0309357-3A
Other languages
English (en)
Inventor
Detlef Grawe
Hagen Gerecke
Peter Hoesel
Annette Eichardt
Sabine Gliesing
Uwe Mueller
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of BR0309357A publication Critical patent/BR0309357A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J1/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J1/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051Estrane derivatives
    • C07J1/0081Substituted in position 17 alfa and 17 beta
    • C07J1/0085Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being a saturated hydrocarbon group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"MéTODO PARA FABRICAR CRISTAIS DE ESTERóIDES, CRISTAIS OBTìVEIS DE ACORDO COM ESSE MéTODO, E FORMULAçõES FARMACêUTICAS". Sendo o tamanho médio de partícula situa-se em uma faixa pré-determinada e cujo tamanho máximo de partícula não ultrapassa um valor pré-determinado, sendo que uma solução supersaturada dos esteróides, é submetida a uma moagem úmida durante a cristalização por meio de um dispositivo para moagem úmida, sendo obtida uma suspensão de grão primário. Além disso, são descritos cristais obtíveis com base nesse método bem como formulações farmacêuticas, que contém esses cristais.
BR0309357-3A 2002-04-23 2003-04-22 Método para fabricar cristais de esteróides, cristais obtìveis de acordo com esse método, e formulações farmacêuticas BR0309357A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10218107A DE10218107A1 (de) 2002-04-23 2002-04-23 Verfahren zum Herstellen von Kristallen von Steroiden, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
PCT/EP2003/004154 WO2003091272A1 (de) 2002-04-23 2003-04-22 Verfahren zum herstellen von kristallen von steroiden, danach erhältliche kristalle und deren verwendung in pharmazeutischen formulierungen

Publications (1)

Publication Number Publication Date
BR0309357A true BR0309357A (pt) 2005-02-22

Family

ID=29264787

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0309357-3A BR0309357A (pt) 2002-04-23 2003-04-22 Método para fabricar cristais de esteróides, cristais obtìveis de acordo com esse método, e formulações farmacêuticas

Country Status (20)

Country Link
US (1) US7148212B2 (pt)
EP (1) EP1497308B1 (pt)
JP (1) JP4490116B2 (pt)
KR (1) KR20040106380A (pt)
CN (1) CN1646555A (pt)
AT (1) ATE340186T1 (pt)
AU (1) AU2003232491A1 (pt)
BR (1) BR0309357A (pt)
CA (1) CA2480004C (pt)
DE (2) DE10218107A1 (pt)
DK (1) DK1497308T3 (pt)
ES (1) ES2274258T3 (pt)
IL (1) IL163986A0 (pt)
MX (1) MXPA04010467A (pt)
NO (1) NO20045023L (pt)
PL (1) PL371340A1 (pt)
PT (1) PT1497308E (pt)
RU (1) RU2315056C2 (pt)
WO (1) WO2003091272A1 (pt)
ZA (1) ZA200409401B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10218109A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
US20080038350A1 (en) * 2006-08-10 2008-02-14 Hagen Gerecke Low-dosage peroral medication for contraception containing crystalline dienogest and ethinyl estradiol
DE502006003892D1 (de) * 2006-08-10 2009-07-16 Bayer Schering Pharma Ag Perorale Arzneiform mit Dienogest und Ethinylestradiol zur Kontrazeption
DE102008037025C5 (de) 2008-08-08 2016-07-07 Jesalis Pharma Gmbh Verfahren zur Herstellung kristalliner Wirkstoff-Mikropartikel bzw. einer Wirkstoffpartikel-Festkörperform
DE102010003711B4 (de) * 2010-04-08 2015-04-09 Jesalis Pharma Gmbh Verfahren zur Herstellung kristalliner Wirkstoffpartikel
RU2642244C2 (ru) * 2010-04-12 2018-01-24 Кларус Терапеутикс, Инк. Оральные фармацевтические композиции сложных эфиров тестостерона и способы лечения недостатка тестостерона с их использованием
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
WO2015173157A2 (en) 2014-05-13 2015-11-19 Akzo Nobel Chemicals International B.V. Process to crystallize chelating agents
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
US11559530B2 (en) 2016-11-28 2023-01-24 Lipocine Inc. Oral testosterone undecanoate therapy
AU2019308326B2 (en) 2018-07-20 2025-07-31 Lipocine Inc. Liver disease
WO2021230308A1 (ja) 2020-05-15 2021-11-18 塩野義製薬株式会社 不純物の生成を抑制した医薬組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3226389A (en) 1962-01-04 1965-12-28 Du Pont 11,11,12,12-tetracyano-naphtho-2,6-quinodimethan and its anion-radical salts
HU209603B (en) 1988-10-05 1994-09-28 Upjohn Co Process for production of solid powders in finalydivided microcristallin form
DE3917617A1 (de) * 1989-05-31 1990-12-06 Boehringer Ingelheim Kg Mikronisierte bioabbaubare partikel, verfahren zur ihrer herstellung und ihre verwendung
FR2668945B1 (fr) 1990-11-12 1993-02-19 Theramex Nouveau procede de cristallisation des substances organiques et les composes ainsi obtenus.
ES2126977T3 (es) 1991-07-10 1999-04-01 Chiyoda Chem Eng Construct Co Procedimento para la produccion de aducto cristalino de bisfenol a y fenol.
NZ248813A (en) * 1992-11-25 1995-06-27 Eastman Kodak Co Polymeric grinding media used in grinding pharmaceutical substances
DE4332283A1 (de) * 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
AU677141B2 (en) * 1993-12-27 1997-04-10 Nippon Soda Co., Ltd. 4-hydroxy-4'-isopropoxydiphenyl sulfone developer composition, wet pulverizing method, and dispersion
US5718388A (en) * 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
US5534270A (en) * 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
CN1183102C (zh) * 1998-12-25 2005-01-05 第一精密化学株式会社 泛酸钙的制备方法
EP1157996A1 (de) * 2000-05-23 2001-11-28 JENAPHARM GmbH Neue Festkörperformen des Mesoprogestins 11Beta-[4E-(Hydroxyiminomethyl)-phenyl]-17Alpha-methoxymethyl-17Beta-methoxy-estra-4,9-dien-3-on
DE10218109A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen

Also Published As

Publication number Publication date
EP1497308A1 (de) 2005-01-19
US7148212B2 (en) 2006-12-12
ZA200409401B (en) 2006-02-22
CN1646555A (zh) 2005-07-27
DE50305122D1 (de) 2006-11-02
MXPA04010467A (es) 2004-12-13
KR20040106380A (ko) 2004-12-17
CA2480004A1 (en) 2003-11-06
DE10218107A1 (de) 2003-11-20
JP4490116B2 (ja) 2010-06-23
US20030216360A1 (en) 2003-11-20
DK1497308T3 (da) 2007-01-29
RU2315056C2 (ru) 2008-01-20
NO20045023L (no) 2004-11-18
CA2480004C (en) 2007-11-13
JP2005524698A (ja) 2005-08-18
RU2004134324A (ru) 2006-02-10
ATE340186T1 (de) 2006-10-15
PT1497308E (pt) 2007-01-31
EP1497308B1 (de) 2006-09-20
IL163986A0 (en) 2005-12-18
AU2003232491A1 (en) 2003-11-10
PL371340A1 (en) 2005-06-13
WO2003091272A1 (de) 2003-11-06
ES2274258T3 (es) 2007-05-16

Similar Documents

Publication Publication Date Title
BR0309357A (pt) Método para fabricar cristais de esteróides, cristais obtìveis de acordo com esse método, e formulações farmacêuticas
DE60332776D1 (de) Herstellung von Delta-9-Tetrahydrocannabinol
CA2225250A1 (en) Bicyclic amino derivatives and pgd2 antagonist containing the same
SE9903760D0 (sv) New compounds
BRPI0408369A (pt) derivados de indol úteis para o tratamento de doenças
BRPI0409227A (pt) composto, composição farmacêutica, uso de um composto, intermediário, e, processo para a preparação de um composto
BR0311494A (pt) Novos indóis substituìdos
BR0112756A (pt) Composto, composição farmacêutica, métodos para o tratamento de doenças mediadas por prostaglandina, de congestão nasal, asma alérgica, e rinite alérgica, e, uso de um composto
BRPI0415657A (pt) derivados de alcanamina de diidrobenzofuranila como agonistas de 5ht2c
SG151254A1 (en) Substituted morpholine and thiomorpholine derivatives
BR0007778A (pt) Peptidila cetonas heterocìclicas úteis como inibidores de triptase
BR9910908A (pt) Indenopirrolocarbazóis ligados em ponte
NO20055562L (no) Substituerte indolin- og indolderivater
BR0304937B1 (pt) composição de antiespumante de silicone encapsulado e processo para a produção de uma composição de antiespumante de silicone encapsulado.
PE20030122A1 (es) Proceso para la preparacion del citalopram racemico y/o del s- o r-citalopram mediante la separacion de una mezcla de r- y s-citalopram
PE20030588A1 (es) Metodos para granulacion humeda de azitromicina
MX2007011695A (es) Derivados de oxindol sustituido, medicamentos que contienen dichos derivados y uso de los mismos.
AR011409A1 (es) Derivados de 16-hidroxi-11-(fenil substituido)-estra-4,9-dieno, su utilizacion, un procedimiento para prepararlos, formulaciones farmaceuticasque comprenden a dichos derivados, y un compuesto utilizable como intermediario para prepararlos
TR200400526T4 (tr) Göz kurumasının tedavisi için lipoksin A4 ve analogları
SE8301008L (sv) Pyrrolacetamider med antiinflammatorisk verkan
AR038658A1 (es) Derivados de 4-aril-2(1h) quinazolinona y 4-aril-quinazolina 2-sustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de un medicamento
BR0309358A (pt) Processo para fabricar cristais de substâncias ativas medicinais, cristais obtìveis com base nesse método e formulações farmacêuticas
AR029461A1 (es) Derivados de 4-fenil-1-piperazinilo, - piperidinilo y -tetrahidropiridilo , composiciones farmaceuticas que los comprenden y el uso de los mismos para la fabricacion de un medicamento
MX2007011698A (es) Derivados de oxindol sustituido, medicamentos que contienen dichos derivados y uso de los mismos.
ATE374195T1 (de) Indazol-3-one und analoga und derivate davon, die die funktion des vanilloid-1-rezeptors (vr1) modulieren

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2051 DE 27/04/2010.